Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19

NCT04911777 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus Disease 2019

Interventions

DRUG: Pentarlandir™ UPPTA
DRUG: Placebo

Sponsor

SyneuRx International (Taiwan) Corp